Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
387 hedge funds and large institutions have $8.08B invested in Intra-Cellular Therapies Inc. in 2024 Q4 according to their latest regulatory filings, with 69 funds opening new positions, 133 increasing their positions, 138 reducing their positions, and 30 closing their positions.
131% more call options, than puts
Call options by funds: $25.4M | Put options by funds: $11M
130% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 30
50% more funds holding in top 10
Funds holding in top 10: 10 → 15 (+5)
14% more capital invested
Capital invested by funds: $7.12B → $8.08B (+$963M)
9% more funds holding
Funds holding: 355 → 387 (+32)
4% less repeat investments, than reductions
Existing positions increased: 133 | Existing positions reduced: 138
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$40.5M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
+$33M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$32.8M |
| 4 |
D.E. Shaw & Co
New York
|
+$13.6M |
| 5 |
O
OrbiMed
New York
|
+$13.4M |
Top Sellers
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$49.3M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$39.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$37.2M |
| 4 |
PA
Perceptive Advisors
New York
|
-$27.4M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$14.9M |
ITCI Hedge Fund Activity: Q4 2024 in Review
387 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2024, worth a combined $8.08B — up 14% from $7.12B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new ITCI positions and 30 closed out — a net gain of 39 holders — while 133 added to existing stakes and 138 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $40.5M. The largest seller was Wasatch Advisors, cutting an estimated $49.3M.
- 387 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2024, up from 355 in Q3 2024.
- Funds reported $8.08B of Intra-Cellular Therapies Inc. stock for Q4 2024, up 14% quarter-over-quarter.
- 69 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2024 and 30 closed out, a net change of +39 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q4 2024 was Adage Capital Partners, an estimated $40.5M added.
- The largest Intra-Cellular Therapies Inc. seller in Q4 2024 was Wasatch Advisors, an estimated $49.3M sold.
Based on aggregated 13F filings for Q4 2024.